Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) has announced the acquisition of a 65,000-square-meter industrial complex in Cisterna di Latina, Italy. This facility aims to enhance the company’s production capabilities in response to rising demand for its drug containment solutions. The new site will employ approximately 190 people and partially utilize renewable energy sources. Operations are set to commence in 2023, boosting the production of standard and EZ-fill® solutions. CEO Franco Moro emphasizes the strategic expansion in a major pharmaceutical hub to better serve customer needs.
Stevanato Group (NYSE: STVN) reported a 10% revenue increase in Q1 2022, totaling €212.1 million. Diluted EPS stood at €0.10, with adjusted diluted EPS at €0.11. The backlog surged 49% to €992.2 million, driven by a 29% rise in high-value solutions. Gross profit margin improved to 31.8%, although production faced temporary slowdowns due to Covid-related absenteeism. The company maintains its fiscal 2022 guidance, projecting revenue between €935 million and €945 million and adjusted diluted EPS between €0.49 and €0.51.
Stevanato Group, a global provider of drug containment and delivery solutions, announced its 2022 Annual General Meeting (AGM) will take place virtually on June 1, 2022, at 4:00 p.m. (CEST). Shareholders can access the meeting agenda, explanatory materials, and voting instructions on the company's investor relations website. Hard copies of the audited financial statements can be requested via email. The press release emphasizes the company's commitment to shareholder engagement and transparency.
Stevanato Group (NYSE: STVN) has entered an exclusive agreement with Owen Mumford to manufacture the Aidaptus® auto-injector. This partnership allows Stevanato to provide engineering and manufacturing support to biopharma companies for drug delivery. Aidaptus® is a flexible, single-use device compatible with multiple syringe sizes and drug viscosities. The collaboration aims to enhance device production efficiency and streamline market access. Stevanato will showcase Aidaptus® at Pharmapack Europe on May 18-19, highlighting its integrated manufacturing capabilities.
Stevanato Group (NYSE: STVN) will release its financial results for Q1 2022 on May 10, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can preregister for the call or access it via a live broadcast. Additionally, a replay of the call will be available through May 24, 2022. Founded in 1949, Stevanato Group offers comprehensive solutions for the pharmaceutical, biotechnology, and life sciences industries, focusing on drug containment, delivery, and diagnostics.
Stevanato Group S.p.A. (NYSE: STVN) has filed Amendment No. 1 (Form 20-F/A) to its 2021 Annual Report with the SEC to add the Interactive Data File and provide additional information. This was filed on April 5, 2022, and the original Form 20-F was submitted on March 8, 2022.
Shareholders can access the Form 20-F/A at www.stevanatogroup.com. A printed copy is available upon request.
Stevanato Group (NYSE: STVN) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, presenting virtually on March 22, 2022 at 9:00 a.m. EDT. A live audio webcast will be accessible on their website, with a replay available for 90 days post-event. The press release includes forward-looking statements regarding the company’s business strategies and recognizes the uncertainty in predicting future events. Founded in 1949, Stevanato Group specializes in drug containment and delivery solutions for the pharmaceutical and biotechnology sectors.
Stevanato Group (NYSE: STVN) has announced the acquisition of a new facility in Zhangjiagang, China, marking a strategic expansion phase. This 32,000 square meter facility will support the production of pre-sterilized EZ-fill® syringes and vials, meeting the growing demand in the biotech sector. Construction is set to begin in spring 2022, with production expected to start in 2023 and operational lines by early 2024. The expansion aims to streamline the drug development supply chain, with the potential to double current production capabilities by the end of 2024.
Stevanato Group (NYSE: STVN) reported a 12.5% increase in fourth quarter revenue to €232.6 million, with diluted EPS at €0.17 and adjusted EPS at €0.13. Full year revenue rose by 27.5% to €843.9 million. The company announced guidance for 2022, expecting revenue between €935 million to €945 million, with adjusted EPS projected at €0.49 to €0.51. Key drivers include strong performance in high-value solutions and demand for Covid-related products. The backlog also increased to €880 million, indicating robust future growth.
Stevanato Group (NYSE: STVN) has secured approximately $95 million from the Biomedical Advanced Research and Development Authority (BARDA) to enhance vial production at its Fishers, Indiana facility. This funding aims to strengthen U.S. capabilities for addressing public health emergencies by expanding the company's manufacturing capacity for standard and EZ-Fill® vials. CEO Franco Moro emphasized that this investment will bolster the U.S. pharmaceutical supply chain and scaling operations in a critical market.